Search

Displaying results 1551 - 1560 of 10000 in total
  1. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. … It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions.

  2. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Atosiban

    go.drugbank.com/drugs/DB09059
    ApprovedInvestigational

    It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.

    Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer Fertigspritze
  4. Drug

    Chlorothiazide

    go.drugbank.com/drugs/DB00880
    ApprovedInvestigationalVet approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

  5. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    a range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development

  6. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.

  7. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.

  8. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.

  9. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  10. Drug

    Trichloroacetate

    go.drugbank.com/drugs/DB11152
    ApprovedInvestigational

    Trichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin. … In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA.

    Categories: Compounds used in a research, industrial, or household setting